✦ LIBER ✦

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

✍ Scribed by A. Inoue; K. Kobayashi; M. Maemondo; S. Sugawara; S. Oizumi; Y. Saijo; A. Genma; S. Morita; K. Hagiwara; T. Nukiwa

Book ID: 119600780
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 46 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)72038-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PP47 First line gefitinib versus first l

PP47 First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group

✍ Y. Minegishi; A. Inoue; K. Kobayashi; A. Gemma; M. Maemondo; S. Oizumi; Y. Saijo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Randomized Phase II Study of Vandetanib

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer

✍ Heymach, J. V.; Paz-Ares, L.; De Braud, F.; Sebastian, M.; Stewart, D. J.; Eberh 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

9007 Randomized, double-blind phase II/I

9007 Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)

✍ Belani, C.; Ramalingam, S.; Kalemkerian, G.; Mok, T.; Rosell, R.; Ahn, M.J.; Sun 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

OP78 EGFR mutations based on circulating

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

A randomized phase III study of the doce

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

✍ Athanasios G Pallis; Sophia Agelaki; Athina Agelidou; Ioannis Varthalitis; Kosta 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 359 KB